Author: Editor

Tian Zhang , MD, Assistant Professor of Medicine, Duke Cancer Institute, explains the anticipated trial results involving I-O, TKIs and biomarkers in renal cell carcinoma (RCC).

Tian Zhang , MD, Assistant Professor of Medicine, Duke Cancer Institute, discusses strategies for the 2nd line renal cell carcinoma (RCC) patients following I-O.

Tian Zhang , MD, Assistant Professor of Medicine, Duke Cancer Institute, provides perspective on treating newly diagnosed renal cell carcinoma (RCC) patients.

Tian Zhang , MD, Assistant Professor of Medicine, Duke Cancer Institute, explains the studies and outcomes in sarcomatoid renal cell cancer and urothelial cancer.

Tian Zhang , MD, Assistant Professor of Medicine, Duke Cancer Institute, explains the design on the outcomes of the PDIGREE trial in metastatic, untreated renal cell carcinoma.

Saad Usmani, MD, Chief, Plasma Cell Disorders Program, Hematologic Malignancies, Levine Cancer Institute/Atrium Health, UNC Chapel Hill School of Medicine shares the data in smoldering multiple myeloma (MM) presented at ASCO 2019.

Saad Usmani, MD, Chief, Plasma Cell Disorders Program, Hematologic Malignancies, Levine Cancer Institute/Atrium Health, UNC Chapel Hill School of Medicine provides outcomes from the MAIA study that compares daratumumab + lenalidomide + dexamethasone versus lenalidomide + dexamethasone in multiple myeloma elderly patients.

Saad Usmani, MD, Chief, Plasma Cell Disorders Program, Hematologic Malignancies, Levine Cancer Institute/Atrium Health, UNC Chapel Hill School of Medicine, compares intravenous daratumumab versus subcutaneous daratumumab.

Debu Tripathy, MD, Professor and Chair, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center explains the results of the SOPHIA trial, a phase III study of chemotherapy plus margetuximab or trastuzumab in HER+ metastatic breast cancer.

Debu Tripathy, MD, Professor and Chair, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center explains how CDK 4/6 inhibitors are being integrated into breast cancer treatment.

Debu Tripathy, MD, Professor and Chair, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center provides the outcomes of the MONALEESA-& trial in premenopausal breast cancer.

Sara Tolaney, MD, Associate Director, Susan F. Smith Center for Womens Cancers, Director Clinical Trials, Breast Oncology, Associate Professor of Medicine, Harvard Medical School provides an overview of the SOPHIA trial, a phase III of chemotherapy plus margetuximab or trastuzumab in HER+ metastatic breast cancer after pertuzumab with 1-3 prior lines of treatment.

Sara Tolaney, MD, Associate Director, Susan F. Smith Center for Womens Cancers, Director Clinical Trials, Breast Oncology, Associate Professor of Medicine, Harvard Medical School elaborates on the efficacy and safety of combination eribulin and pembrolizumab in metastatic breast cancer.

Sara Tolaney, MD, Associate Director, Susan F. Smith Center for Womens Cancers, Director Clinical Trials, Breast Oncology, Associate Professor of Medicine, Harvard Medical School shares the results of ImPassion130 study, a phase III adding atezolizumab to the 1st line chemotherapy with nab-paclitaxel in patients with PD-L1 positive metastatic triple-negative cancer (TNBC).

Sara Tolaney, MD, Associate Director, Susan F. Smith Center for Womens Cancers, Director Clinical Trials, Breast Oncology, Associate Professor of Medicine, Harvard Medical School discusses the outcomes from the MONALEESA-7 trial in premenopausal metastatic breast cancer.         premenopausal metastatic breast cancer, monaleesa-7 trial, outcomes

Leonard Saltz, MD, Executive Director for Clinical Value and Sustainability, Colorectal Oncology Section, Memorial Sloan Kettering Cancer Center discusses the value of liquid biopsy and where it is ready for routine practice in CRC.

Leonard Saltz, MD, Executive Director for Clinical Value and Sustainability, Colorectal Oncology Section, Memorial Sloan Kettering Cancer Center addresses molecular profiling in the treatment of colorectal cancer (CRC).

Leonard Saltz, MD, Executive Director for Clinical Value and Sustainability, Colorectal Oncology Section, Memorial Sloan Kettering Cancer Center shares the results from the APACT study, a phase III trial involving adjuvant nab-paclitaxel plus gemcitabine versus gemcitabine alone for surgically resected pancreatic adenocarcinoma.

Leonard Saltz, MD, Executive Director for Clinical Value and Sustainability, Colorectal Oncology Section, Memorial Sloan Kettering Cancer Center addresses whether current data will change the way we treat colorectal cancer.

Leonard Saltz, MD, Executive Director for Clinical Value and Sustainability, Colorectal Oncology Section, Memorial Sloan Kettering Cancer Center evaluates the complexities of managing advanced/refractory metastatic colorectal cancer (mCRC).

Ravi Salgia, MD, Professor and Chair, Department of Medical Oncology and Therapeutics Research, Associate Director for Clinical Sciences, Arthur and Rosalie Kaplan Endowed Chair in Medical Oncology, City of Hope, opens up about the top challenges in managing non-small cell lung cancer (NSCLC) in patients.

Ravi Salgia, MD, Professor and Chair, Department of Medical Oncology and Therapeutics Research, Associate Director for Clinical Sciences, Arthur and Rosalie Kaplan Endowed Chair in Medical Oncology, City of Hope, explains how 2nd line patients who received Keytruda or other PD-L1 targeting agents can be treated.

Ravi Salgia, MD, Professor and Chair, Department of Medical Oncology and Therapeutics Research, Associate Director for Clinical Sciences, Arthur and Rosalie Kaplan Endowed Chair in Medical Oncology, City of Hope explains the ideal patient to receive Alimta plus Keytrude based on data and results from KEYNOTE-189.

Ravi Salgia, MD, Professor and Chair, Department of Medical Oncology and Therapeutics Research, Associate Director for Clinical Sciences, Arthur and Rosalie Kaplan Endowed Chair in Medical Oncology, City of Hope on treating non-squamous, non-small cell lung cancer (NSCLC) patients who express high levels of PD-L1.

Ravi Salgia, MD, Professor and Chair, Department of Medical Oncology and Therapeutics Research, Associate Director for Clinical Sciences, Arthur and Rosalie Kaplan Endowed Chair in Medical Oncology, City of Hope, identifies strategies for recognizing PD-L1 status.

Ravi Salgia, MD, Professor and Chair, Department of Medical Oncology and Therapeutics Research, Associate Director for Clinical Sciences, Arthur and Rosalie Kaplan Endowed Chair in Medical Oncology, City of Hope, showcases some molecular tests that are utilized prior to treating advanced NSCLC.

Ravi Salgia, MD, Professor and Chair, Department of Medical Oncology and Therapeutics Research, Associate Director for Clinical Sciences, Arthur and Rosalie Kaplan Endowed Chair in Medical Oncology, City of Hope addresses on germline mutations and the impact they have on non-small cell lung cancer (NSCLC) patients.

Naiyer Rizvi, MD Price Family Professor of Medicine and Director of Thoracic Oncology, Co-Director of Cancer Immunotherapy, Columbia Irving Medical Center addresses on the future of non-small cell lung cancer (NSCLC) drug development.

Naiyer Rizvi, MD Price Family Professor of Medicine and Director of Thoracic Oncology, Co-Director of Cancer Immunotherapy, Columbia Irving Medical Center provides his thoughts on the role of blood TMB versus tissue TMB as a biomarker for lung cancer patients.

Naiyer Rizvi, MD Price Family Professor of Medicine and Director of Thoracic Oncology, Co-Director of Cancer Immunotherapy, Columbia Irving Medical Center explains the role of PD-L1 and TMB biomarkers in treating lung cancer with both single agent immuno-oncology (I-O) and I-O combinations.

Naiyer Rizvi, MD, Price Family Professor of Medicine and Director of Thoracic Oncology, Co-Director of Cancer Immunotherapy, Columbia Irving Medical Center explains the results from KEYNOTE-001 which evaluated pembrolizumab in advanced non-small cell lung cancer (NSCLC).

Naiyer Rizvi, MD, Price Family Professor of Medicine and Director of Thoracic Oncology, Co-Director of Cancer Immunotherapy, Columbia Irving Medical Center discusses biomarker roles in identifying lung cancer patients who are most likely to benefit from therapies.

Danny Rischin, MD, Division of Cancer Medicine, Department of Medical Oncology, Peter MacCallum Cancer Centre, Professor of Medicine, University of Melbourne discusses the updated data for the treatment of cutaneous squamous cell carcinoma (cSCC).

Danny Rischin, MD, Division of Cancer Medicine, Department of Medical Oncology, Peter MacCallum Cancer Centre, Professor of Medicine, University of Melbourne explains why stratification PD-L1 score in KEYNOTE-048 is important for head and neck cancer.

Danny Rischin, MD, Division of Cancer Medicine, Department of Medical Oncology, Peter MacCallum Cancer Centre, Professor of Medicine, University of Melbourne provides insight on KEYNOTE-048 investigating pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma.

Robert Rifkin, MD, McKesson Biosimilars, Associate Chair, Rocky Mountain Cancer Centers explains the promise of bispecific antibodies in multiple myeloma (MM) treatment for patients.

Robert Rifkin, MD, McKesson Biosimilars, Associate Chair, Rocky Mountain Cancer Centers explains the different combinations that are available and still in develop for the convenience of multiple myeloma (MM) patients.

Robert Rifkin, MD, McKesson Biosimilars, Associate Chair, Rocky Mountain Cancer Centers explains maintenance regimens for multiple myeloma (MM) patients.

Robert Rifkin, MD, McKesson Biosimilars, Associate Chair, Rocky Mountain Cancer Centers discusses the outcomes from the ECOD trial in smoldering multiple myeloma (MM).

Robert Rifkin, MD, McKesson Biosimilars, Associate Chair, Rocky Mountain Cancer Centers showcases the difference from daratumumab and isatuximab and whether the drug is showing promise as a treatment for MM.

Robert Rifkin, MD, McKesson Biosimilars, Associate Chair, Rocky Mountain Cancer Centers explains the significance of the prolonged progression-free survival in patients with relapsed/refractory multiple myeloma (MM) if treating with isatuximab.

Paul Richardson, MD, Clinical Program Leader, Director of Clinical Research, Jerome Lipper Multiple Myeloma, Institute Physician, Harvard Medical School describes the updated FORTE trial data in multiple myeloma (MM).

Paul Richardson, MD, Clinical Program Leader, Director of Clinical Research, Jerome Lipper Multiple Myeloma, Institute Physician, Harvard Medical School provides results from the ECOG trial in smoldering multiple myeloma (MM).

Paul Richardson, MD, Clinical Program Leader, Director of Clinical Research, Jerome Lipper Multiple Myeloma, Institute Physician, Harvard Medical School considers whether isatuximab can remain a treatment option for relapsed/refractory multiple myeloma (MM).

Paul Richardson, MD, Clinical Program Leader, Director of Clinical Research, Jerome Lipper Multiple Myeloma, Institute Physician, Harvard Medical School discusses the prolonged progression-free survival in patients with relapsed/refractory multiple myeloma (MM) if treated with isatuximab.

Debra Patt, MD, Executive Vice President, Strategic Initiatives, Academic Programs, Texas Oncology addresses the policies proposed to drig pricing.

Debra Patt, MD, Executive Vice President, Strategic Initiatives, Academic Programs, Texas Oncology shares the transition from volume to value in the oncology space.

Debra Patt, MD, Executive Vice President, Strategic Initiatives, Academic Programs, Texas Oncology describes the factors that influence cost in novel therapeutic interventions.

Debra Patt, MD, Executive Vice President, Strategic Initiatives, Academic Programs, Texas Oncology explains the role of CDK 4/6 inhibitors in advanced breast cancer and discusses whether they are interchangeable in treatment planning for patients.

Debra Patt, MD, Executive Vice President, Strategic Initiatives, Academic Programs, Texas Oncology shares the results of the ImPassion130, a phase III study that adds atezolizumab to 1st line chemotherapy with nab-paclitaxel in patients with PD-L1 positive metastatic triple negative breast cancer (TNBC).